Rani Therapeutics (NASDAQ:RANI) focuses on the development of oral biologics that aim to replace traditional subcutaneous or intravenous injections, addressing a major market need for more patient-friendly drug delivery methods. Their innovative technology, known as the RaniPill™ capsule, is designed to navigate through the stomach and release its payload directly into the intestine, with the aim of achieving similar levels of drug absorption as injections but without the needles. Projects primarily revolve around applying this technology to a range of biologic drugs, including those for diabetes, arthritis, and other chronic conditions. Objectives include advancing these projects through clinical trials, achieving regulatory approvals, and ultimately commercializing their platform to improve patient outcomes and adherence for biologic treatments.